No evidence for cardiotoxicity of miltefosine.
作者信息
Dorlo Thomas P C
机构信息
Department of Pharmacy & Pharmacology, Antoni van Leeuwenhoek Hospital/Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Pharmacy, Uppsala University, Uppsala, Sweden.
出版信息
An Bras Dermatol. 2022 Jul-Aug;97(4):548-549. doi: 10.1016/j.abd.2022.03.002. Epub 2022 May 30.
Abstract
摘要
相似文献
1
No evidence for cardiotoxicity of miltefosine.没有证据表明米替福新具有心脏毒性。
An Bras Dermatol. 2022 Jul-Aug;97(4):548-549. doi: 10.1016/j.abd.2022.03.002. Epub 2022 May 30.
2
Comparison of cardiotoxicity between N-methyl-glucamine and miltefosine in the treatment of American cutaneous leishmaniasis.N-甲基葡糖胺与米替福新治疗美洲皮肤利什曼病时心脏毒性的比较。
An Bras Dermatol. 2021 Jul-Aug;96(4):502-504. doi: 10.1016/j.abd.2021.02.002. Epub 2021 May 15.
3
No evidence for cardiotoxicity of miltefosine - Reply.关于米替福新心脏毒性的无证据——回复。
An Bras Dermatol. 2022 Jul-Aug;97(4):549-550. doi: 10.1016/j.abd.2022.03.001. Epub 2022 Jun 3.
4
Miltefosine--the long-awaited therapy for visceral leishmaniasis?米替福新——内脏利什曼病期待已久的治疗方法？
N Engl J Med. 1999 Dec 9;341(24):1840-2. doi: 10.1056/NEJM199912093412411.
5
Miltefosine in visceral leishmaniasis.米替福新治疗内脏利什曼病
Lancet Infect Dis. 2003 Feb;3(2):70. doi: 10.1016/s1473-3099(03)00512-7.
6
[Treatment of visceral leishmaniasis: efficacy and limits of miltefosine].[内脏利什曼病的治疗：米替福新的疗效与局限性]
Sante. 2001 Oct-Dec;11(4):257-8.
7
Miltefosine for visceral leishmaniasis.米替福新治疗内脏利什曼病。
N Engl J Med. 2000 Mar 23;342(12):894-5. doi: 10.1056/NEJM200003233421214.
8
Miltefosine for visceral leishmaniasis.米替福新治疗内脏利什曼病。
N Engl J Med. 2000 Mar 23;342(12):895. doi: 10.1056/NEJM200003233421215.
9
Miltefosine: great expectations against visceral leishmaniasis.米替福新：对抗内脏利什曼病的巨大期望。
J Postgrad Med. 2003 Jan-Mar;49(1):101-3. doi: 10.4103/0022-3859.911.
10
Miltefosine for Indian visceral leishmaniasis.米替福新治疗印度内脏利什曼病。
N Engl J Med. 2003 Feb 27;348(9):857-8; author reply 857-8.
本文引用的文献
1
Comparison of cardiotoxicity between N-methyl-glucamine and miltefosine in the treatment of American cutaneous leishmaniasis.N-甲基葡糖胺与米替福新治疗美洲皮肤利什曼病时心脏毒性的比较。
An Bras Dermatol. 2021 Jul-Aug;96(4):502-504. doi: 10.1016/j.abd.2021.02.002. Epub 2021 May 15.
2
Factors affecting the electrocardiographic QT interval in malaria: A systematic review and meta-analysis of individual patient data.影响疟疾心电图 QT 间期的因素：一项个体患者数据的系统评价和荟萃分析。
PLoS Med. 2020 Mar 5;17(3):e1003040. doi: 10.1371/journal.pmed.1003040. eCollection 2020 Mar.
3
Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis.米替福新：一种治疗利什曼病的药理学和治疗功效的综述。
J Antimicrob Chemother. 2012 Nov;67(11):2576-97. doi: 10.1093/jac/dks275. Epub 2012 Jul 24.
4
Oral miltefosine for Indian visceral leishmaniasis.口服米替福新治疗印度内脏利什曼病。
N Engl J Med. 2002 Nov 28;347(22):1739-46. doi: 10.1056/NEJMoa021556.
Zotero 插件